Title: Deputy Director (Retired)
Company: National Center of Toxicogenomics
Location: Chapel Hill, North Carolina, United States
James K. Selkirk, PhD, retired deputy director from the National Center of Toxicogenomics, has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in the field of biochemistry.
With four decades of experience to his credit, Dr. Selkirk is a proven leader in the field of biochemistry. Prior to retiring in 2009, he excelled as the deputy director of the National Center of Toxicogenomics. Likewise, he operated as a member of the Orange County Planning Board from 1997 to 2009. He also previously served as a special assistant to the scientific director for technology development at the National Institute Environmental Health Sciences from 1997 to 2000. He originally joined the National Institute in 1985 as the chief of carcinogenesis and toxicology evaluation, and from 1989 to 1992, he was the associate director of the division for toxicology research and testing. Furthermore, from 1992 to 1997, he served as the chief of carcinogen mechanism group for laboratory molecular carcinogenesis. Over the course of his career, Dr. Selkirk dedicated himself to his scholarly pursuits as well, having authored numerous research articles and papers.
Before embarking on his vocational journey, Dr. Selkirk honorably served in the United States Army Chemical Corp between 1959 and 1961. He subsequently pursued a higher education, originally earning a Bachelor of Science in environmental chemistry at the Environmental College of Forestry in 1964. In conclusion of his collegiate efforts, Dr. Selkirk ultimately achieved a PhD in biochemistry at Upstate Medical University (formerly the Upstate Medical Center) in 1969. To commemorate his achievements in the field, he was selected in the 2,000 Outstanding Intellectuals of the 21st Century in 2016. Attributing his success to his love of science, Dr. Selkirk is most notably proud to have been formally recognized for his work in chemical cross-carcinogenesis.
For more information, please visit:
Press Release
Contact Dr. Selkirk: